Clinical Trial

PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis

Name: PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis — clinical trial record (NCT07119918)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PICASSO

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

An investigator-initiated, prospective, multicenter, randomized, double-blind, placebo-controlled trial comparing the 1-year incidence of stroke in patients with AIS or TIA within 7 days who are treated with either placebo or Recaticimab.

Trial Details

NCT Number	NCT07119918
Lead Sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions	Symptomatic Intracranial Atherosclerotic Stenosis
Enrollment	5,276 participants
Start Date	2025-09-01
Primary Completion	2029-12-01 (estimated)
Study Completion	2029-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-08-13